Login to Your Account



Wilex Drops ccRCC Drug Rencarex Interim Analysis

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, November 23, 2011
Wilex AG is taking the unusual step of canceling a planned interim analysis of data from a pivotal Phase III trial of its clear cell renal cell carcinoma (ccRCC) drug Rencarex (girentuximab) and seeking permission from European and U.S. drug regulators to complete a final data analysis based on an amended protocol.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription